About this episode
Rabid demand for weight-loss drugs like Ozempic and Wegovy is altering US society and transforming the healthcare industry. Rapid Response host Bob Safian guides us through the upheaval and lessons, talking with CEO Zach Reitano of Ro, a telehealth platform that has ridden the wave to a $7 billion valuation. Reitano shares why he chose obesity-treatment as his company’s “hero product,” the impact of weight-loss drugs on industries beyond health-care, and why the potential of GLP-1s like Ozempic mirrors that of AI.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Get every episode summarized
Each time Rapid Response publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Rapid Response
On's 16-year overnight success: Zendaya, Federer, and outrunning competition
Rapid Response
NFL Kickoff: the science gets more damning, but the money keeps growing
Rapid Response
Masters of Scale: Always be the challenger, with Savannah Bananas founder Jesse...
Rapid Response
When AI agents do your shopping, everything changes, with Shopify’s Jess Hertz
Rapid Response